Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 10201 - 10225 of 12422 in total
Paliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous neurotrophines. Studies show that use of paliroden increased the rate of formation of both neural progenitors and mature neurons. It is indicated for use in Alzheimer's Disease and Parkinson’s.
Investigational
Matched Description: … Studies show that use of paliroden increased the rate of formation of both neural progenitors and mature ... Paliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous …
Apramycin is an aminoglycoside antibiotic and has a bactericidal action against many gram-negative bacteria. Apramycin is a structurally unique antibiotic that contains a bicyclic sugar moiety and a monosubstituted deoxystreptamine. It is not approved for use in humans.
Experimental
Vet approved
Halofuginone is a low molecular weight quinazolinone alkaloid, and a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. Halofuginone also effectively suppresses tumor progression and metastasis in mice. Collgard Biopharmaceuticals is developing halofuginone for the treatment of scleroderma and received orphan drug designation from the U.S....
Investigational
Vet approved
Matched Description: … Halofuginone is a low molecular weight quinazolinone alkaloid, and a potent inhibitor of collagen alpha1 ... Collgard Biopharmaceuticals is developing halofuginone for the treatment of scleroderma and received …
Picoplatin is a cytotoxic platinum compound in clinical development for the treatment of patients with solid tumors. It causes apoptosis (cell death) by binding to DNA and interfering with DNA replication and transcription.
Investigational
Matched Description: … Picoplatin is a cytotoxic platinum compound in clinical development for the treatment of patients with …
Becocalcidiol is a vitamin D(3) analogue which has not caused hypercalcaemia or significant irritation in preclinical trials.
Investigational
AM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation. It is being developed by Amira.
Investigational
Matched Description: … AM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential ... to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation …
Telapristone acetate, an orally-available, selective progesterone receptor modulator, is in development to alleviate symptoms associated with both uterine fibroids and endometriosis.
Investigational
Black cohosh (Actaea racemosa or Cimicifuga racemosa), a member of the buttercup family, is a perennial plant which native to North America. Historical names for this plant include snakeroot, black bugbane, rattleweed, macrotys, and rheumatism weed. Black cohosh has a long history of use. Native Americans used it for its...
Experimental
Matched Description: … Black cohosh has a long history of use. ... [A32543] The American College of Obstetrics and Gynecology guidelines on the use of botanicals, such ... as black cohosh, for the management of menopausal symptoms the use of for up to six months, especially …
Huperzine B is a novel acetylcholinesterase inhibitor.
Investigational
Tirapazamine, also known as SR-4233, is an experimental anticancer drug that is activated in hypoxic conditions. This activation is very useful as this hypoxic state is found in human solid tumors in a common phenomenon known as tumor hypoxia. Hence, tirapazamine is solely activated in those hypoxic areas of solid...
Investigational
Matched Description: … Hence, tirapazamine is solely activated in those hypoxic areas of solid tumors. ... For all these reasons, the combination of tirapazamine with other anticancer treatments is highly recommended …
GB-13 is a genetically engineered recombinant protein consisting of an IL13Ra2-targeted genetically engineered mutant of IL-13 and PE4E, a derivative of Pseudomonas exotoxin A.
Investigational
Matched Description: … mutant of IL-13 and PE4E, a derivative of Pseudomonas exotoxin A. ... GB-13 is a genetically engineered recombinant protein consisting of an IL13Ra2-targeted genetically engineered …
Absence of molybdenum cofactor leads to accumulation of toxic levels of sulphite and neurological damage usually leading to death within months of birth, due to the lack of active sulfite oxidase.
Experimental
Matched Description: … Absence of molybdenum cofactor leads to accumulation of toxic levels of sulphite and neurological damage ... usually leading to death within months of birth, due to the lack of active sulfite oxidase. …
CP-39,332 is a serotonin-norepinephrine reuptake inhibitor (SNRI). It is part of a group of monoamine reuptake inhibitor stereoisomers including tametraline (1R,4S-), CP-24,442 (1S,4R-), CP-22,185 (cis-), and CP-22,186 that show varying efficiency. However, none of the members of this stereoisomers has been marketed.
Experimental
Matched Description: … However, none of the members of this stereoisomers has been marketed. ... It is part of a group of monoamine reuptake inhibitor stereoisomers including tametraline (1R,4S-), CP …
PI-103 is an inhibitor of p110α of class I PI3K.
Investigational
Matched Description: … PI-103 is an inhibitor of p110α of class I PI3K.[A253092] …
Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing jaundice.
Investigational
Matched Description: … WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing ... Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of
Entolimod has been used in trials studying the treatment of Mucositis, Tongue Cancer, Colorectal Cancer, Stage IVA Verrucous Carcinoma of the Larynx, and Stage IVB Verrucous Carcinoma of the Larynx, among others.
Investigational
Matched Description: … , Stage IVA Verrucous Carcinoma of the Larynx, and Stage IVB Verrucous Carcinoma of the Larynx, among ... Entolimod has been used in trials studying the treatment of Mucositis, Tongue Cancer, Colorectal Cancer …
Efavaleukin alfa is a fusion protein consisting of interleukin mutein fused to the C-terminus of an immunoglobulin G Fc domain by way of a G4S linker. It is under investigation in clinical trial NCT03422627 (Safety and Efficacy of AMG 592 in Subjects With Steroid Refractory Chronic Graft Versus Host Disease).
Investigational
Matched Description: … G Fc domain by way of a G4S linker. ... Efavaleukin alfa is a fusion protein consisting of interleukin mutein fused to the C-terminus of an immunoglobulin ... It is under investigation in clinical trial NCT03422627 (Safety and Efficacy of AMG 592 in Subjects With …
NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause of death worldwide. In May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of...
Investigational
Matched Description: … of death worldwide. ... NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and ... In May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265. …
Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the minor groove of DNA.[A182036,A182039] It's association with severe myelotoxicity lead to the end of its development in favour of α-halogenoacrylamide derivatives such as brostallicin, which have a favourable cytotoxicity/myelotoxicity ratio.[A182039,A182045] Newer generations of DNA...
Experimental
Matched Description: … minor groove of DNA. ... Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the ... [A182036,A182039] It's association with severe myelotoxicity lead to the end of its development in favour …
Elezanumab is under investigation in clinical trial NCT03737812 (A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis).
Investigational
Matched Description: … Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis). ... Elezanumab is under investigation in clinical trial NCT03737812 (A Study to Assess the Safety and Efficacy of
MK-0773 is under investigation in clinical trial NCT00529659 (A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(mk-0773-005)).
Investigational
Matched Description: … MK-0773 is under investigation in clinical trial NCT00529659 (A Study of the Safety and Efficacy of MK ... -0773 in Women With Sarcopenia (Loss of Muscle Mass)(mk-0773-005)). …
APR-548 is an analog of eprenetapopt and a reactivator of mutant p53.
Investigational
Matched Description: … APR-548 is an analog of [eprenetapopt] and a reactivator of mutant p53. …
MUL001 is live attenuated strain of Salmonella typhimurium being investigated for the treatment of schwannomas.
Investigational
Matched Description: … MUL001 is live attenuated strain of _Salmonella typhimurium_ being investigated for the treatment of
Brilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder. Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder...
Investigational
Matched Description: … As of May 2015, it is in phase III clinical trials for schizophrenia. ... Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of bipolar disorder, major ... investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of
5alpha-androstane-3beta,17alpha-diol is the unspecified form of the steroid, normally a major metabolite of testosterone with androgenic activity. It has been implicated as a regulator of gonadotropin secretion.
Experimental
Matched Description: … of [testosterone] with androgenic activity. ... It has been implicated as a regulator of gonadotropin secretion. ... 5alpha-androstane-3beta,17alpha-diol is the unspecified form of the steroid, normally a major metabolite …
Displaying drugs 10201 - 10225 of 12422 in total